Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 3/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3777477 | 0.88 | CMA1 (0.58) | CMA1MEN1ALDH1A1KMT2AKDM4E | |
| SCHEMBL3781519 | 0.87 | CMA1 (0.55) | CMA1KDM4ESMN1; SMN2CA9CA12 | |
| SCHEMBL3786874 | 0.84 | CMA1 (0.59) | CMA1KDM4ECA9CA12CA1 | |
| SCHEMBL3790909 | 0.75 | CMA1 (0.61) | CMA1MEN1ALDH1A1KMT2AKDM4E | |
| SCHEMBL7462562 | 0.74 | CMA1 (0.72) | CMA1MEN1ALDH1A1KMT2AKDM4E | |
| SCHEMBL3786922 | 0.72 | CMA1 (0.69) | CMA1MEN1KMT2AKDM4ECA9 | |
| SCHEMBL3780425 | 0.72 | CMA1 (0.69) | CMA1CA9CA12CA1CA2 | |
| SCHEMBL7463672 | 0.71 | CMA1 (1.00) | CMA1SMN1; SMN2CA9CA12CA1 | |
| SCHEMBL3785095 | 0.71 | CMA1 (0.67) | CMA1CA9CA12CA1CA2 | |
| SCHEMBL3780426 | 0.71 | CMA1 (0.67) | CMA1MEN1KMT2AKDM4ECA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029695-A1 | METHOD OF TREATING DERMATITIS COMPRISING ADMINISTERING A CHYMASE INHIBITOR | ASUBIO PHARMA CO., LTD. (JP) | 2010-02-04 | — | — | US | disclosed |
| US-7169951-B2 | Quinazoline derivatives and pharmaceutical applications thereof | DAIICHI ASUBIO PHARMA CO., LTD. (JP) | 2007-01-30 | — | — | US | disclosed |
| EP-1174151-B1 | THERAPEUTIC TREATMENT OF EOSINOPHILIA USING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT | DAIICHI ASUBIO PHARMA CO LTD (JP) | 2007-01-24 | — | — | EP | disclosed |
| EP-1192950-B1 | THERAPEUTIC DRUGS FOR DERMATITIS EXHIBITING A BIPHASIC SKIN REACTION CONTAINING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT | DAIICHI ASUBIO PHARMA CO LTD (JP) | 2006-07-26 | — | — | EP | disclosed |
| EP-1114035-B1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEREOF | DAIICHI ASUBIO PHARMA CO LTD (JP) | 2006-05-17 | — | — | EP | disclosed |
| US-20050148608-A1 | Quinazoline derivatives and pharmaceutical applications thereof | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-07-07 | — | — | US | disclosed |
| US-6867214-B1 | Quinazoline derivatives and pharmaceutical applications thereof | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-03-15 | — | — | US | disclosed |
| US-6677344-B2 | Chymase inhibitor for the treatment of eosinophilia | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2004-01-13 | — | — | US | disclosed |
| US-6500835-B2 | FOR PROPHYLAXIS AND THERAPY OF FIBROSIS INVOLVING EXTRACELLULAR MATRIX DYSBOLISM HAVING A CHYMASE INHIBITOR AS AN EFFECTIVE INGREDIENT; SIDE EFFECT REDUCTION | SUNTORY LIMITED (JP) | 2002-12-31 | — | — | US | disclosed |
| US-20020187989-A1 | Preventive or therapeutic drugs for various eosinophilia-related diseases containg chymase inhibitors as the active ingredient | ASUBIO PHARMA CO., LTD. (JP) | 2002-12-12 | — | — | US | disclosed |
| US-20020183338-A1 | PREVENTIVE OR THERAPEUTIC DRUGS FOR FIBROSIS CONTAINING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT | ASUBIO PHARMA CO., LTD. (JP) | 2002-12-05 | — | — | US | disclosed |
| EP-1192949-A1 | PREVENTIVE OR THERAPEUTIC DRUGS FOR FIBROSIS CONTAINING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT | SUNTORY LIMITED (JP) | 2002-04-03 | — | — | EP | disclosed |
| EP-1192950-A1 | PREVENTIVE OR THERAPEUTIC DRUGS FOR DERMATITISES CONTAINING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT | SUNTORY LIMITED (JP) | 2002-04-03 | — | — | EP | disclosed |
| EP-1174151-A1 | PREVENTIVE OR THERAPEUTIC DRUGS FOR VARIOUS EOSINOPHILIA-RELATED DISEASES CONTAINING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT | SUNTORY LIMITED (JP) | 2002-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020187989-A1 | Preventive or therapeutic drugs for various eosinophilia-related diseases containg chymase inhibitors as the active ingredient | CMA1, SERPINB1, EPX | CMA1 1/4885MEN1 1571/4885ALDH1A1 541/4885 |
| US-20050148608-A1 | Quinazoline derivatives and pharmaceutical applications thereof | CMA1, ACE, ACE2 | CMA1 1/4885MEN1 3759/4885ALDH1A1 1525/4885 |
| US-20020183338-A1 | PREVENTIVE OR THERAPEUTIC DRUGS FOR FIBROSIS CONTAINING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT | CMA1, MMP1, SERPINB1 | CMA1 1/4885MEN1 1665/4885ALDH1A1 460/4885 |
| US-20100029695-A1 | METHOD OF TREATING DERMATITIS COMPRISING ADMINISTERING A CHYMASE INHIBITOR | CMA1, DNPEP, SERPINB1 | CMA1 1/4885MEN1 4531/4885ALDH1A1 3296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.